Defunct Company
Total Trials
13
As Lead Sponsor
As Collaborator
0
Total Enrollment
1,733
NCT04514419
Treatment of Breast Cancer With Trastuzumab + HS627/ Pertuzumab + Docetaxel
Phase: Phase 3
Role: Lead Sponsor
Start: Jun 30, 2020
Completion: Nov 20, 2021
NCT04361812
Comparison of Pharmacokinetics and Safety of HS632 and Xolair® With a Single Injection
Phase: Phase 1
Start: Oct 15, 2020
Completion: Dec 31, 2021
NCT06001580
A Phase I Study of BR101 Injection Alone in Subjects With Advanced Solid Tumors
Start: Aug 11, 2021
Completion: Jun 30, 2026
NCT05323981
Comparison of Pharmacokinetics and Safety of HS627(2 Specifications) Versus PERJETA With a Single Injection
Start: Apr 11, 2022
Completion: Oct 9, 2022
NCT05351697
Phase I Clinical Study of BR105 Injection
Start: Apr 30, 2022
Completion: Sep 30, 2025
NCT06018506
A Phase I Study of BR108 in Hematological Malignancies
Start: Mar 27, 2023
Completion: Mar 2, 2026
NCT05987605
Phase I/II Clinical Study of 1A46 Drug Substance
Start: Sep 12, 2023
Completion: Nov 1, 2024
NCT06038058
A Phase I Study of BRY812 for Injection Alone in Subjects With Advanced Malignancies
Start: Oct 31, 2023
Completion: Dec 31, 2028
NCT06126718
Phase I Randomized, Open-label, Parallel-controlled, Pharmacokinetic and Safety Study of BR201 Injection Versus Cosentyx in Healthy Male Subjects
Start: Feb 21, 2024
Completion: Aug 19, 2024
NCT06289894
A Study of BRY805 in Participants With Advanced Solid Tumors
Start: Mar 31, 2024
Completion: Sep 30, 2027
NCT06388902
A Phase I Study of BR115 for Injection Alone in Subjects With Advanced Solid Malignancies
Start: Apr 30, 2024
NCT06642909
A Phase II Study of Zuberitamab Injection in Patients With Primary Membranous Nephropathy
Phase: Phase 2
Start: Oct 31, 2024
Completion: Dec 31, 2027
NCT06937957
A Study of BR111 in Patients With Advanced Malignancies
Start: Apr 30, 2025